Clinical pharmacokinetics of nefazodone

Clinical Pharmacokinetics

Volumn 33, Issue 4, 1997, Pages 260-275

  Greene, Douglas S ^a   Barbhaiya, Rashmi H ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPRAZOLAM; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CIMETIDINE; CYCLOSPORIN; CYTOCHROME P450; DIGOXIN; DRUG METABOLITE; FLUOXETINE; HALOPERIDOL; LITHIUM; NEFAZODONE; PROPRANOLOL; SEROTONIN 2 RECEPTOR; TERFENADINE; THEOPHYLLINE; TRIAZOLAM; WARFARIN;

AGE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; FOOD INTAKE; HUMAN; KIDNEY DISEASE; LIVER DISEASE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE;

EID: 0030929237     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199733040-00002     Document Type: Review

References (51)

1. Feigher JP, Pambakian R, Fowler RC, et al. A comparison of nefazodone, imipramine and placebo in patients with moderate to severe depression. Psychopharmacol Bull 1989; 25: 219-21
2. Eison AS, Eison MS, Torrente JR, et al. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 1990; 26: 311-5
3. Hyslop DK, Allen LE, Taylor DP, et al. Triazolo antidepressants do not inhibit monoamine oxidase. Drug Rev Res 1988; 12: 77-9
4. Taylor DP, Smith DE, Hyslop DK, et al. Receptor binding and atypical antidepressant drug discovery. In: O'Brien RA, editor. Receptor binding in drug research. New York: Marcel Dekker, 1986: 151-65
5. Mayol RF, Cole CA, Luke GM, et al. Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab Dispos 1994; 22: 304-11
6. D'Amico MF, Roberts DL, Robinson DS, et al. Placebo controlled dose-ranging trial designs in phase II development of nefazodone. Psychopharmacol Bull 1990; 26: 247-50
7. Barbhaiya RH, Marathe PH, Greene DS, et al. Safety, tolerance and preliminary pharmacokinetic of nefazodone after administration of single and multiple oral doses to healthy adult male volunteers: a double blind, phase I study. J Clin Pharmacol 1995; 35: 974-84
8. Fontaine R. Novel serotonergic mechanisms and clinical experience with nefazodone [abstract]. Clin Neuropharmacol 1992; 15 (1 Suppl.): 99A
9. Franc JE, Duncan GF, Farmen RH, et al. High performance liquid chromatographic method for the determination of nefazodone and its metabolites in human plasma using laboratory methods. J Chromatography 1991; 570: 129-38
10. Franklin M. Determination of nefazodone and its metabolites in plasma by high-performunce liquid chromatography with coulometric detection. J Pharm Biometric Analysis 1993; 11: 1109-13
11. Barbhaiya RH, Buch AB, Greene DS. Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. Br J Clin Pharmacol 1996; 42: 573-81
12. Burbhaiya RH, Buch AB, Greene DS. A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. J Clin Psychopharmacol 1996; 16: 19-25
13. Barbhaiya RH, Shukla UA, Greene DS. Single dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment. Eur J Clin Pharmacol 1995; 49: 221-8
14. Barbhaiya RH, Shukla UA, Natarajan CS, et al. Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis. Clin Pharmacol Ther 1995; 58: 390-8
15. Dockens RC, Greene DS, Barbhaiya RH. The lack of effect of food on the bioavailability of nefazodone tablets. Biopharm Drug Dispos 1996; 17: 135-43
16. Kaul S, Shukla UA, Barbhaiya RH. Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses. J Clin Pharmacol 1995; 35: 830-9
17. Ferry N, Bernard N, Cuisinaud G, et al. Influence of hepatic impairment on the pharmacokinetics of nefazodone and two of its metabolites after single and multiple oral doses. Fundam Clin Pharmacol 1994; 8: 463-73
18. Marathe PH, Lee JS, Greene DS, et al. Comparison of the steady pharmacokinetics of nefazodone after administration of 200 mg twice daily or 400 mg once daily in the morning or evening. Br J Clin Pharmacol 1996; 41: 21-7
19. Barbhaiya RH, Shukla UA, Chaikin P, et al. Nefazodone pharmacokinetics: assessment of nonlinearity, intrasubject variability and time to attain steady state plasma concentrations after dose escalation and de-escalation. Eur J Clin Pharmacol 1996; 50: 101-7
20. Barbhaiya RH, Brady ME, Shukla UA, et al. Steady state pharmacokinetics of nefazodone in subjects with normal and impaired renal function. Eur J Clin Pharmacol 1995; 49: 229-35
21. 14C]nefazodone in humans. Drug Metab Dispos 1996; 24: 91-5
22. Marathe PH, Salazar DE, Greene DS, et al. Absorption and presystemic metabolism of nefazodone administered at different regions of the gastrointestinal tract of humans. Pharm Res 1995; 12: 1716-21
23. Data on file, Bristol-Myers Squibb, 1996
24. Barbhaiya RH, Shukla UA, Kroboth PD, et al. Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. J Clin Psychopharmacol 1995; 15: 320-6
25. Shukla UA, Marathe PH, Lubudde JA, et al. Pharmacokinetics of nefazodone in the dog following single oral administration. Eur J Drug Metab Pharmacokinet 1992; 17: 301-8
26. Shukla UA, Kaul S, Marathe PH, et al. Pharmacokinetics of nefazodone following multiple escalating doses in the dog. Eur J Drug Metab Pharmacokinet 1992; 17: 309-18
27. 14C]nefazodone in the dog. Drug Metab Dispos 1993; 21: 502-7
28. von Moltke LL, Greenblatt DJ, Harmatz JS, et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Expt Ther 1996; 276: 370-9
29. Schmider J, Greenblatt DJ, von Moltke LL, et al. Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan ()- and N-demethylation. Br J Clin Pharmacol 1996; 41: 339-43
30. von Moltke LL, Greenblatt DJ, Xiang Duan S, et al. Phenacetin o-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants and venlafaxine. Psychopharmacology 1997. In press
31. Pentikainen PJ, Valisalmi L, Himberg JJ, et al. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol 1989; 29: 272-7
32. Robin DW, Lee MH, Hasan SS, et al. Triazolam in cirrhosis: pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1993; 54: 630-6
33. Buch A, Shukla U, Pittman K, et al. Pharmacokinetics of nefazodon in extensive and poor metabolism of dextromethorphan. Pharm Res 1993; 10: S314
34. Kroboth PD, Folan MM, Lush RM, et al. Coadministration of nefazodone and benzodiazepines: I. Pharmacodynamic assessment. J Clin Psychopharmacol 1995; 15: 306-19
35. Greene DS, Salazar DE, Dockens RC, et al. Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam. J Clin Psychopharmacol 1995; 15: 399-408
36. Greene DS, Salazar DE, Dockens RC, et al. Coadministration of nefazodone and benzodiazepines: IV. A pharmacokinetic interaction study with lorazepam. J Clin Psychopharmacol 1945; 15: 409-16
37. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Interaction of triazolum and ketoconazole. Lancet 1995; 345: 191
38. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, et al. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-uptake antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994; 38: 23-31
39. Ameer B, Greenblatt DJ, Lorazepam: a review of its clinical pharmacologic properties and therapeutic uses. Drugs 1981; 21: 161-200
40. Barbhaiya RH, Shukla UA, Greene DS, et al. Investigation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol. J Clin Psychopharmacol 1996; 16: 26-34
41. Marino MR, Langenbacher KM, Uderman HD. Interaction of nefazodone and fluoxetine. Clin Pharmacol Ther 1996; 59: 180
42. Ashton AK, Wolin RE. Nefazodone induced carbamazepine toxicity. Am J Psychiatry 1996; 153: 733
43. Laroudie C, Salazar DE, Decourt J-P. Carbamazepine-nefazodone interaction in healthy volunteers. World Congress of Psychiatry; 1996 Aug; Madrid
44. Laroudie C, Salazar DE, Decourt J-P. Coadministration of nefazodone does not modify pharmacokinetic parameters of lithium at steady-state in healthy volunteers. World Congress of Psychiatry; 1996 Aug; Madrid
45. Frewer LJ, Lader M. The effects of nefazodone, imipramine and placebo, alone and combined with alcohol, in normal subjects. Int J Clin Psychopharmacol 1993; 8: 13-20
46. Barbhaiya RH, Shukla UA, Greene DS. Luck of interaction between nefazodone and cimetidine: a steady state pharmacokinetic study in humans. Br J Clin Pharmacol 1995; 40: 161-5
47. Salazar DE, Dockens RC, Milbrath RL, et al. Pharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone coadministration in healthy subjects. J Clin Pharmacol 1995; 35: 730-8
48. Salazar DE, Marathe PH, Fulmor IE, et al. Pharmacokinetic and pharmucodynamics evaluation during coadministration of nefazodone and propranolol in healthy men. J Clin Pharmacol 1995; 35: 1109-18
49. Dockens RC, Rapoport D, Roberts D, et al. Lack of an effect of nefazodone on the pharmacokinetics and pharmacodynamics of theophylline during concurrent administration in patients with chronic obstructive pulmonary disease. Br J Clin Pharmacol 1995; 40: 598-602
50. Helms-Smith KM, Curtis SL, Hutton RC. Apparent interaction between nefazodone and cyclosporine. Ann Intern Med 1996; 125: 424
51. Robinson DS, Marcus RN, Archibald DG, et al. Therapeutic dose range of nefazodone in the treatment of major depression. J Clin Psychiatry 1996; 57 (Suppl. 2): 6-9